肝病药物市场：按治疗方法、最终用户划分 - 全球预测 2023-2030

全球肝病药物市场预计将大幅成长，2023年将达到167.7亿美元，2030年将达到290.4亿美元，年复合成长率为8.14%。

FPNV定位矩阵

FPNV定位矩阵对于评估全球肝病治疗市场至关重要。透过检查业务策略和产品满意度的关键指标，我们对供应商进行全面评估，使您能够根据您的特定需求做出明智的资讯。这种进阶分析将供应商分为四个像限，并取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市占率分析

市场占有率分析可以深入了解供应商在特定市场领域的当前地位。比较供应商对总收入、基本客群和其他关键指标的贡献，可以帮助公司更好地了解他们在争夺市场份额时的表现以及面临的情况。该分析还揭示了特定行业的竞争程度、累积和合併的优势以及研究基准年的合併特征。

本报告提供了以下几点见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开发：提供有关利润丰厚的新兴市场的详细资讯，并分析其在成熟市场的渗透率。

3. 市场多元化：提供有关新产品发布、未开发地区、最新发展和投资的详细资讯。

4.市场趋势：全面了解COVID-19、俄罗斯-乌克兰衝突和高通膨的累积影响。

5.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、法规状况、专利状况、製造能力等进行综合评估。

6. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告回答了以下问题：

1.全球肝病治疗药物市场规模及预测如何？

2.在预测期内，COVID-19对全球肝病治疗药物市场的阻碍因素与影响为何？

3.预测期内全球肝病治疗药物市场有哪些产品/细分市场/应用/领域值得投资？

4.你们在全球肝病药物市场的竞争策略是什么？

5.全球肝病药物市场的技术趋势与法律规范是什么？

6.全球肝病治疗药物市场主要厂商的市占率为何？

7. 哪些型态和策略性倡议被认为适合进入全球肝病药物市场？

目录

第1章前言

第2章调查方法

第3章执行摘要

第4章市场概况

第5章市场洞察

• 市场动态
  • 促进因素
    • 全球肝病发生率飙升
    • 政府和私人组织在宣传和疫苗接种计划方面加强力
    • 生活方式的改变，例如饮酒和吸烟
  • 抑制因素
    • 对可能的药物副作用的担忧
  • 机会
    • 预防和治疗肝病的持续研究和开发活动
    • 延长治疗药物的专利有效期限
  • 任务
    • 严格的政府法规和高昂的研发成本
• 市场趋势
• COVID-19 的累积影响
• 俄罗斯-乌克兰衝突的累积影响
• 高通膨的累积效应
• 波特五力分析
• 价值炼和关键路径分析
• 法律规范
• 客户客製化

第6章治疗药物市场

• 抗病毒药物
• 化疗药物
• 皮质类固醇
• 免疫球蛋白
• 免疫抑制药物
• 标靶治疗

第7章治疗药物市场：依最终使用者分类

• 门诊手术中心
• 医院

第8章北美与南美洲肝病药物市场

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美国

第9章亚太地区肝病治疗药物市场

• 澳洲
• 中国
• 印度
• 印尼
• 日本
• 马来西亚
• 菲律宾
• 新加坡
• 韩国
• 台湾
• 泰国
• 越南

第10章欧洲、中东和非洲肝病治疗药物市场

• 丹麦
• 埃及
• 芬兰
• 法国
• 德国
• 以色列
• 义大利
• 荷兰
• 奈及利亚
• 挪威
• 波兰
• 卡达
• 俄罗斯
• 沙乌地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公国
• 英国

第11章竞争形势

• FPNV定位矩阵
• 市占率分析：主要企业
• 竞争情境分析：主要企业

第12章上市公司名单

第13章附录

• 讨论指南
• 关于许可证和定价

The Global Liver Diseases Therapeutics Market is forecasted to grow significantly, with a projected USD 16.77 billion in 2023 at a CAGR of 8.14% and expected to reach a staggering USD 29.04 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Liver Diseases Therapeutics Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Liver Diseases Therapeutics Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Treatment, market is studied across Anti Viral Drugs, Chemotherapy Drugs, Corticosteroids, Immunoglobulin, Immunosuppressant Drugs, and Targeted Therapy. The Targeted Therapy is projected to witness significant market share during forecast period.

Based on End User, market is studied across Ambulatory Surgery Centers and Hospitals. The Ambulatory Surgery Centers is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Liver Diseases Therapeutics Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Liver Diseases Therapeutics Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Liver Diseases Therapeutics Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Liver Diseases Therapeutics Market?

4. What is the competitive strategic window for opportunities in the Global Liver Diseases Therapeutics Market?

5. What are the technology trends and regulatory frameworks in the Global Liver Diseases Therapeutics Market?

6. What is the market share of the leading vendors in the Global Liver Diseases Therapeutics Market?

7. What modes and strategic moves are considered suitable for entering the Global Liver Diseases Therapeutics Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Liver Diseases Therapeutics Market, by Treatment, 2022 vs 2030
• 4.3. Liver Diseases Therapeutics Market, by End User, 2022 vs 2030
• 4.4. Liver Diseases Therapeutics Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Surge in the incidences of liver diseases worldwide
    • 5.1.1.2. Increasing government and private organizations initiatives toward awareness and vaccination programs
    • 5.1.1.3. Changing lifestyles such as consumption of alcohol and smoking
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns over probable side effects of the medication
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing research and development activities for prevention and cure of liver diseases
    • 5.1.3.2. Increasing patent expiration of therapeutics
  • 5.1.4. Challenges
    • 5.1.4.1. Strict government regulations and high cost involved in R&D
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Liver Diseases Therapeutics Market, by Treatment

• 6.1. Introduction
• 6.2. Anti Viral Drugs
• 6.3. Chemotherapy Drugs
• 6.4. Corticosteroids
• 6.5. Immunoglobulin
• 6.6. Immunosuppressant Drugs
• 6.7. Targeted Therapy

7. Liver Diseases Therapeutics Market, by End User

• 7.1. Introduction
• 7.2. Ambulatory Surgery Centers
• 7.3. Hospitals

8. Americas Liver Diseases Therapeutics Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Liver Diseases Therapeutics Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Liver Diseases Therapeutics Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. FPNV Positioning Matrix
• 11.2. Market Share Analysis, By Key Player
• 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

• 13.1. Discussion Guide
• 13.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. LIVER DISEASES THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. LIVER DISEASES THERAPEUTICS MARKET SIZE, 2022 VS 2030
• FIGURE 3. LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2022 VS 2030 (%)
• FIGURE 5. LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2022 VS 2030 (%)
• FIGURE 6. LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 7. LIVER DISEASES THERAPEUTICS MARKET DYNAMICS
• FIGURE 8. LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 9. LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. LIVER DISEASES THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 15. LIVER DISEASES THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. LIVER DISEASES THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 5. LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTI VIRAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANT DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 12. LIVER DISEASES THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 17. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 18. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 19. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 20. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 21. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 22. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 23. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 24. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 25. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 27. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 28. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 30. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 31. AUSTRALIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 32. AUSTRALIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 33. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 34. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 35. INDIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 36. INDIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 37. INDONESIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 38. INDONESIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 39. JAPAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 40. JAPAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 41. MALAYSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 42. MALAYSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 43. PHILIPPINES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 44. PHILIPPINES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 45. SINGAPORE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 46. SINGAPORE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 47. SOUTH KOREA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 48. SOUTH KOREA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 49. TAIWAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 50. TAIWAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 51. THAILAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 52. THAILAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 53. VIETNAM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 54. VIETNAM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 55. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 57. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 58. DENMARK LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 59. DENMARK LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 60. EGYPT LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 61. EGYPT LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 62. FINLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 63. FINLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 64. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 65. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 66. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 67. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 68. ISRAEL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 69. ISRAEL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 70. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 71. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 72. NETHERLANDS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 73. NETHERLANDS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 74. NIGERIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 75. NIGERIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 76. NORWAY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 77. NORWAY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 78. POLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 79. POLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 80. QATAR LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 81. QATAR LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 82. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 83. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 84. SAUDI ARABIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 85. SAUDI ARABIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 88. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 89. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 90. SWEDEN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 91. SWEDEN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 92. SWITZERLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 93. SWITZERLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 94. TURKEY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 95. TURKEY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 96. UNITED ARAB EMIRATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 97. UNITED ARAB EMIRATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 98. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 99. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 100. LIVER DISEASES THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 101. LIVER DISEASES THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 102. LIVER DISEASES THERAPEUTICS MARKET LICENSE & PRICING